Working… Menu

Pazopanib in Von Hippel-Lindau (VHL) Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01436227
Recruitment Status : Active, not recruiting
First Posted : September 19, 2011
Last Update Posted : May 13, 2019
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:

The goal of this clinical research study is to learn if pazopanib can help to control Von Hippel-Lindau Syndrome VHL. The safety of this drug will also be studied.

This is an investigational study. Pazopanib is FDA approved and commercially available for kidney cancer. Its use to treat VHL is investigational.

Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells.

Pazopanib will be provided at no cost to you during this study.

Up to 40 patients will take part in this study. All will be enrolled at MD Anderson.

Condition or disease Intervention/treatment Phase
Von Hippel-Lindau Syndrome Drug: Pazopanib Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome
Actual Study Start Date : January 2012
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2022

Arm Intervention/treatment
Experimental: Pazopanib
800 mg by mouth once daily for up to six, four week cycles.
Drug: Pazopanib
800 mg by mouth once daily for up to six, four week cycles.
Other Name: GW786034

Primary Outcome Measures :
  1. RECIST Overall Response (OR) Rate = Number of Participants with Complete Response and Partial Response (CR+PR) at 24 weeks [ Time Frame: 24 weeks ]
    Modified Response Evaluation Criteria in Solid Tumors (RECIST), evaluation of target lesions (organ-specific). Complete Response (CR): Disappearance all target lesions; Partial Response (PR): > 30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): > 20% increase in sum LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1 or > new lesions; Stable Disease (SD): Neither sufficient shrinkage for PR nor sufficient increase for PD, reference smallest sum LD since treatment started.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow up. Procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol.
  2. Eastern Cooperative Oncology Group (ECOG) performance status of </= 2
  3. Genetically confirmed diagnosis of VHL or measurable disease consistent with the clinical diagnosis of VHL. (Please refer to criterion #5)
  4. Measurable disease criteria: At least one measurable VHL related lesion, which is undergoing surveillance, and patient is not at immediate risk of needing intervention for this or other lesions. Biopsy is not required given the known likely etiology and natural history in the setting of a positive genetic test. a.) Brain: asymptomatic hemangioblastoma, >/= 0.5 cm ; b) Spine: asymptomatic hemangioblastoma, >/= 0.5 cm ; c) Renal: solid mass suspicious for RCC >/= 1 cm or cystic mass (Bosniak 3-4) >/= 1 cm. ; d) Pancreas: solid mass >/= 1cm and </= 3 cm suspicious for neuroendocrine tumor, or neuroendocrine tumor > 3 cm but not considered operable. ; e) Eye: asymptomatic peripapillary and/or macular hemangioblastoma, any size ; f) Adrenal: asymptomatic or controlled pheochromocytoma greater than 1cm in size
  5. Patients may have received prior VHL-related systemic therapy, provided not within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib.
  6. Adequate organ system function as defined: a) Absolute neutrophil count (ANC) >/= 1.5 X 10^9/L ; b) Hemoglobin >/= 9 g/dL (5.6 mmol/L) ; c) Platelets >/= 100 X 10^9/L ; d) Prothrombin time (PT) or international normalized ratio (INR) </= 1.2 X ULN ; e) Activated partial thromboplastin time (aPTT) </= 1.2 X ULN ; f) Total bilirubin </= 1.5 X ULN ; g) Alanine amino transferase (ALT) and Aspartate aminotransferase (AST) </= 2.0 X ULN ; h) Serum creatinine </= 2.0 mg/dL (133 µmol/L) Or, if >2.0 mg/dL: Calculated creatinine clearance (ClCR) (appropriate appendix) >/= 50 mL/min ; i) Urine Protein to Creatinine Ratio (UPC; appropriate appendix) <1
  7. A female is eligible to enter and participate in this study if she is of: Non-childbearing potential including a) any female who has had a surgical procedure rendering her incapable of becoming pregnant. ; b) Subjects not using hormone replacement therapy (HRT) must have experienced total cessation of menses for >/= 1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone (FSH) value >40 mIU/mL and an estradiol value < 40 pg/mL (<140 pmol/L). ; c) Subjects using HRT must have experienced total cessation of menses for >/= 1 year and be greater than 45 years of age OR have had documented evidence of menopause based on FSH and estradiol concentrations prior to initiation of HRT ; Childbearing potential, including any female who has had a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception.
  8. # 8 Cont.) GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:a) Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the dosing period, and for at least 21 days after the last dose of investigational product. b) Oral contraceptive c) Injectable progestogen. d) Implants of levonorgestrel. e) Estrogenic vaginal ring f) Percutaneous contraceptive patches g) Intrauterine device (IUD) h) Male partner sterilization i) Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository). ; Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug.

Exclusion Criteria:

  1. Prior malignancy. Note: Subjects who have had another non VHL related malignancy and have been disease-free for 2 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.
  2. Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: a) Active peptic ulcer disease ; b) Known intraluminal metastatic lesion/s with risk of bleeding ; c) Inflammatory bowel disease (e.g. ulcerative colitis, Chrohn's disease), or other gastrointestinal conditions with increased risk of perforation ; d) History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment.
  3. Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: a) Malabsorption syndrome ; b) Major resection of the stomach or small bowel.
  4. Presence of uncontrolled infection
  5. Corrected QT interval (QTc) > 480 msecs using Bazett's formula
  6. History of any one or more of the following cardiovascular conditions within the past 6 months: a) Cardiac angioplasty or stenting ; b) Myocardial infarction ; c) Unstable angina ; d) Coronary artery bypass graft surgery ; e) Symptomatic peripheral vascular disease ; f) Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
  7. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of >/= 140 mmHg or diastolic blood pressure (DBP) of >/= 90mmHg]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be <140/90 mmHg in order for a subject to be eligible for the study (see Section 3.0. for details on BP control and re-assessment prior to study enrollment).
  8. History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
  9. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major).
  10. Evidence of active bleeding or bleeding diathesis
  11. Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
  12. Unable or unwilling to discontinue use of prohibited medications list for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study.
  13. Treatment with any of the following anti-cancer therapies: a) radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR ; b) chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib
  14. Any ongoing toxicity from prior investigational therapy that is >Grade 1 and/or that is progressing in severity, except alopecia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01436227

Layout table for location information
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Layout table for investigator information
Principal Investigator: Eric Jonasch, MD M.D. Anderson Cancer Center

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT01436227     History of Changes
Other Study ID Numbers: 2011-0465
NCI-2011-03285 ( Registry Identifier: NCI CTRP )
First Posted: September 19, 2011    Key Record Dates
Last Update Posted: May 13, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by M.D. Anderson Cancer Center:
Von Hippel-Lindau Syndrome
Von Hippel-Lindau related lesion
Additional relevant MeSH terms:
Layout table for MeSH terms
Von Hippel-Lindau Disease
Pathologic Processes
Neurocutaneous Syndromes
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn